New Search

If you are not happy with the results below please do another search

Generic filters

50 search results for:


Safety Signals Force Merck and Enanta to Scrap HIV and HBV Programs

Merck’s HIV strategy took a major hit as a “very important” aspect, MK-8507, was paused in development after patients experienced a low white blood cell count. East coast neighbor Enanta is also feeling the sting of a failed program with HBV trials, as the Massachusetts biotech is dropping the oral hepatitis B virus RNA destabilizer EDP-721 after healthy participants experienced safety signals.